Vote No
An Act to amend the Food and Drugs Act (warning label on alcoholic beverages)
Overall, the bill introduces a new regulatory requirement with indirect and uncertain economic benefits, while offering limited alignment with growth, competitiveness, or investment objectives. Health and potential fiscal benefits exist but are not structured to materially advance Build Canada’s core prosperity goals.
Suggestions to improve alignment:
No question period cards yet.
Potential long-run health benefits could marginally raise labour participation and reduce public health costs, but the bill adds compliance costs and does not directly drive growth.
Imposes a new mandatory labeling regime and prohibits sales without it, adding regulatory burden and reducing business flexibility.
Health warning labels may improve workforce productivity over time, but near-term effects are compliance costs and packaging changes with unclear competitiveness gains.
The requirement applies to domestic sales; impacts on export volumes are indirect and uncertain.
Creates compliance costs and operational complexity (especially for small producers) without catalyzing R&D or capital formation.
A low-cost public health intervention that can reduce alcohol-related disease burden and downstream healthcare expenditures, improving fiscal efficiency.
No tax changes are proposed.
It is a narrow labeling mandate with modest macroeconomic relevance, not a transformative economic reform.
Did we get the builder vote wrong?
Email [email protected]